Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
October 06, 2020 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
FDA Granted Pediatric Disease Designation for OXi-4503
September 16, 2020 09:00 ET
|
Mateon Therapeutics
AGOURA HILLS, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that the US...
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Atopic Dermatitis
March 24, 2020 08:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health and healthy...
LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome
January 10, 2020 07:00 ET
|
LogicBio Therapeutics
– LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome – – The collaboration agreement grants Takeda an...
LogicBio Therapeutics Extends Sponsored Research Agreement with Oregon Health & Science University to Explore Translation of Pharmaceutically-Driven Selective Advantage for Future GeneRide™ Candidates
December 17, 2019 08:00 ET
|
LogicBio Therapeutics
CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric...
OWP Pharmaceuticals Announces a Second IND Approval and Patent Application: The First-Ever Liquid Oral Suspension Formulation of Lamotrigine for the Treatment of Epilepsy and Bipolar Disorder
December 03, 2019 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Dec. 03, 2019 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Global Pulse Oximeter Market is Set to Reach USD 1,913.2 million by 2024, Observing a CAGR of 7.6% during 2019–2024: VynZ Research
November 25, 2019 13:15 ET
|
VynZ Research
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- The global pulse oximeter market is expected to grow at a CAGR of 7.6% during the forecast period with its market size predicted to reach USD 1,913.2...
OWP Pharmaceuticals Announces IND Approval and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Topiramate for the Treatment of Epilepsy and Migraine
November 20, 2019 08:00 ET
|
OWP Pharmaceuticals
NAPERVILLE, Ill., Nov. 20, 2019 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
Renovation of Children's Hospital Rehab Unit Helps Children Walk with "ZeroG" Technology
October 25, 2019 09:26 ET
|
Children's Hospital of The King's Daughters
Norfolk, Va., Oct. 25, 2019 (GLOBE NEWSWIRE) -- A smile slowly spread across the face of 5-year-old Lucas Guinn as he felt a harness gently lift him aloft to walk across the room. Another...
Our Lady of the Lake Children’s Hospital Opens Doors Tomorrow, Oct. 5
October 04, 2019 15:00 ET
|
Franciscan Missionaries of Our Lady Health System
Baton Rouge, LA, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Our Lady of the Lake Children’s Hospital will open its doors tomorrow at 6 a.m., beginning a new chapter in the healthcare ministry’s history...